AMP-activated protein kinase (AMPK) activators have been in use for many years to treat type 2 diabetes, but recent data demonstrate that these compounds can inhibit AKT-derived pro-survival effects and induce apoptosis in cancer cells [53]. This evidence concerns the gene AKT1 and cancer.